 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2012;5(4):316-320
Original Article
The clinical utility of anti-chromatin antibodies as measured by BioPlex 2200 in the
diagnosis of systemic lupus erythematosus versus other rheumatic diseases
Nilanjana Bose, Xiaofeng Wang, Majula Gupta, Qingping Yao
Departments of Rheumatic and Immunologic Diseases and Quantitative Health Sciences/Biostatistics and Clinical Pathology,
Cleveland Clinic, Cleveland, OH, USA
Received June 29, 2012; accepted July 31, 2012; Epub August 22, 2012; Published September 15, 2012
Abstract: Background: The detection of autoantibodies is indispensable to systemic lupus erythematosus (SLE). Bioplex 2200 ANA
screen is a multiplex immunoassay system that allows simultaneous determination of autoantibodies to extractable nuclear antigens
(ENA) including anti-chromatin antibodies (ACAs). However, the clinical significance of the ACAs by this new method in SLE patients
has not been studied in comparison with other rheumatic disorders. We performed a retrospective study of patients with rheumatic
diseases to assess the diagnostic value of the antichromatin antibodies (ACAs) by Bioplex 2200 method in systemic lupus
erythematosus (SLE). Methods: Adult patients with rheumatic complaints seen by rheumatologists at the Cleveland Clinic between
January 2008 and February 2010 were screened for positive anti-ENA antibodies by the Bioplex 2200. Patients with positive anti-ENA
antibodies were classified into two populations based upon the presence and absence of the ACAs. We retrospectively studied the
clinical and laboratory data of these patients. Results: A total of 764 subjects with positive anti-ENA antibodies were screened,
including 115 with positive ACAs. There were 93 SLE patients consisting of 58 with positive ACAs and 35 with negative ACAs. The
sensitivity, specificity, positive predictive value and negative predictive value of the ACAs in SLE were 62.4%, 91.5%, 50.4% and 94.6%
respectively. Apart from SLE, positive ACAs were associated with mixed connective tissue disease (MCTD)/undifferentiated CTD
(UCTD) and other autoimmune diseases. No correlation was found between the ACAs and lupus glomerulonephritis or anti-dsDNA
antibodies. Conclusions: Measurement of the ACAs by the Bioplex 2200 is specific for diagnosing SLE but not useful for differentiating
between SLE and MCTD/UCTD. (IJCEM1206004).
Keywords: Systemic lupus erythematosus, anti-chromatin antibodies, anti-ENA antibodies, BioPlex 2200
Address all correspondence to:
Dr. Qingping Yao
Department of Rheumatic and Immunologic Diseases/A50
Cleveland Clinic, 9500 Euclid Avenue
Cleveland, OH 44195, USA.
Tel: (216) 444-5625; Fax: (216) 445-7569
E-mail: yaoq@ccf.org
Original Article
The clinical utility of anti-chromatin antibodies as measured by BioPlex 2200 in the
diagnosis of systemic lupus erythematosus versus other rheumatic diseases
Nilanjana Bose, Xiaofeng Wang, Majula Gupta, Qingping Yao
Departments of Rheumatic and Immunologic Diseases and Quantitative Health Sciences/Biostatistics and Clinical Pathology,
Cleveland Clinic, Cleveland, OH, USA
Received June 29, 2012; accepted July 31, 2012; Epub August 22, 2012; Published September 15, 2012
Abstract: Background: The detection of autoantibodies is indispensable to systemic lupus erythematosus (SLE). Bioplex 2200 ANA
screen is a multiplex immunoassay system that allows simultaneous determination of autoantibodies to extractable nuclear antigens
(ENA) including anti-chromatin antibodies (ACAs). However, the clinical significance of the ACAs by this new method in SLE patients
has not been studied in comparison with other rheumatic disorders. We performed a retrospective study of patients with rheumatic
diseases to assess the diagnostic value of the antichromatin antibodies (ACAs) by Bioplex 2200 method in systemic lupus
erythematosus (SLE). Methods: Adult patients with rheumatic complaints seen by rheumatologists at the Cleveland Clinic between
January 2008 and February 2010 were screened for positive anti-ENA antibodies by the Bioplex 2200. Patients with positive anti-ENA
antibodies were classified into two populations based upon the presence and absence of the ACAs. We retrospectively studied the
clinical and laboratory data of these patients. Results: A total of 764 subjects with positive anti-ENA antibodies were screened,
including 115 with positive ACAs. There were 93 SLE patients consisting of 58 with positive ACAs and 35 with negative ACAs. The
sensitivity, specificity, positive predictive value and negative predictive value of the ACAs in SLE were 62.4%, 91.5%, 50.4% and 94.6%
respectively. Apart from SLE, positive ACAs were associated with mixed connective tissue disease (MCTD)/undifferentiated CTD
(UCTD) and other autoimmune diseases. No correlation was found between the ACAs and lupus glomerulonephritis or anti-dsDNA
antibodies. Conclusions: Measurement of the ACAs by the Bioplex 2200 is specific for diagnosing SLE but not useful for differentiating
between SLE and MCTD/UCTD. (IJCEM1206004).
Keywords: Systemic lupus erythematosus, anti-chromatin antibodies, anti-ENA antibodies, BioPlex 2200
Address all correspondence to:
Dr. Qingping Yao
Department of Rheumatic and Immunologic Diseases/A50
Cleveland Clinic, 9500 Euclid Avenue
Cleveland, OH 44195, USA.
Tel: (216) 444-5625; Fax: (216) 445-7569
E-mail: yaoq@ccf.org
